Silexion Activates First Site for Phase 2/3 Pancreatic Cancer Trial
SLXN is trading near its 52-week low of $2.204 (14% below the low).
Summary
Silexion has activated the first clinical site for its Phase 2/3 trial of SIL204, a pan-KRAS siRNA candidate for locally advanced pancreatic cancer. The Tel Aviv Sourasky Medical Center (Ichilov) is now cleared to begin patient screening, with first dosing expected in the coming weeks. This marks the transition from regulatory preparation to active clinical execution, following a series of authorizations from Israeli and German health authorities. The trial targets a high-unmet-need population where KRAS mutations drive ~90% of cases and approved therapies are lacking. While preclinical data showed broad mutation coverage and a predecessor compound suggested survival benefits, pancreatic cancer trials carry high risk. The company has a micro-cap valuation and recent going concern warning, so clinical progress is critical. Additional site activations in Israel and Germany are in parallel, with safety and interim data readouts as the next potential catalysts.
At the time of this announcement, SLXN was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $2.20 to $223.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: FinanceWire.